利妥昔单抗在初治原发性胃B细胞淋巴瘤中的作用  

Effect of rituximab on primary gastric B cell iymphoma

作　　者：崔莹莹[1] 张明智[1] 李鑫[1] 孙振昌[1] 武晓龙[1] 冷长森 张蕾[1] 付晓瑞[1] 李玲[1] 张旭东[1] 常宇[1] 南飞飞[1] 李兆明[1] 严家芹[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,450052 [2]郑州大学附属肿瘤医院

出　　处：《中国实用医刊》2015年第8期42-43,共2页Chinese Journal of Practical Medicine

摘　　要：目的分析原发性胃B细胞淋巴瘤的临床特征、诊治和预后，探讨利妥昔单抗在原发性胃B细胞淋巴瘤中的作用。方法回顾性分析2005年10月至2013年8月郑州大学第一附属医院收治的初治原发性胃B细胞淋巴瘤患者的临床特征、诊治效果、治疗方法对预后的影响。纳入73例患者，男23例，女50例，男女比例1：2．2，最常见症状为腹痛，分为CHOP组和RCHOP组。结果5年总生存率CHOP组为64％，RCHOP组为95％（P=0．026）。单因素分析显示Lugano分期和乳酸脱氢酶（LDH）显著影响预后。结论化疗可作为原发性胃B细胞淋巴瘤的一线治疗方案，利妥昔单抗可能有利于提高远期生存率。Lugano分期和LDH是重要的预后影响因素。Objective To analyze the clinical characteristics, diagnosis, therapy and prognosis of newly diagnosed primary gastric B cell lymphoma and to investigate the efficacy of rituximab. Methods From October 2005 to August 2013, seventy three patients were reviewed retrospectively in the aspects of clinical characteristics, diagnosis, therapy and prognostic factors. Twenty three males and fifty females were enrolled. The most common symptom was stomachache. Patients underwent chemotherapy were divided into CHOP group and CHOP combined with rituximab group. Results The 5-year total survival rate was 64% in CHOP group and 95% in RCHOP group （P =0. 026）. Univariate analysis showed that LDH and Lugano staging were independent factors of prognosis. Conclusions Chemotherapy can be the first-line therapy of primary gastric B cell lymphoma. The overall survival rate can be increased by adding rituximab to chemotherapy. The Lugano stage and LDH are important prognostic factors.

关 键 词：淋巴瘤 胃 化疗 利妥昔单抗 

分 类 号：R733.4[医药卫生—肿瘤]